

IN THE SPECIFICATION:

The disclosure is objected to because of the following informalities: At page 1, line 11, "fluorescent" is misspelled. At page 2, line 19 and 25 "chlorobenzoxazole" is misspelled. At page 2, line 26, "oC" should be re-written as °C.

At page 1, line 11 ~~fluorecent~~ fluorescent

At page 2 lines 19 and 25, ~~Chlorobezoxazole~~ chlorobenzoxazole

At page 2, line 26, ~~oC~~ °C.

The amendment filed August 31, 2001 is objected to under 35 U.S.C. 132 because it introduces new matter into the disclosure. Applicants withdraw the new matter filed August 31, 2001 in response to the requirement for a sequence listing mailed by the Office on July 5, 2001.